CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? [Globe and Mail, The (Toronto, Canada)]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Globe and Mail, The
Investors should keep in mind that this biotech stock is risky. CRISPR Therapeutics (NASDAQ: CRSP) , a mid-cap biotech company, achieved a major milestone when it earned approval for the first CRISPR-based medicine in 2023. However, the company has significantly underperformed broader equities in the past five years. The stock is bouncing back, though, and it has had momentum over the trailing-12-month period. Things could get even better as CRISPR Therapeutics makes clinical progress throughout the year. With plenty of catalysts ahead, is now a good time to buy the stock? Image source: Getty Images. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Multiple data readouts on the horizon CRISPR Therapeutics is a gene editing specialist . The company's only approved product, Casgevy -- which it commercializes
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- CRISPR Therapeutics (CRSP) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? [Yahoo! Finance]Yahoo! Finance
- Assessing CRISPR Therapeutics (CRSP) Valuation After Recent Share Price Performance [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (CRSP) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- This Biotech Has a Pipeline That Could Redefine Its Entire Therapeutic Area [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 2/12/26 - Miss
CRSP
Sec Filings
- 4/21/26 - Form ARS
- 4/21/26 - Form DEFA14A
- 4/21/26 - Form DEF
- CRSP's page on the SEC website